de Agostini A, Lijnen H R, Pixley R A, Colman R W, Schapira M
J Clin Invest. 1984 Jun;73(6):1542-9. doi: 10.1172/JCI111360.
To define the factors responsible for the inactivation of the active fragment derived from Factor XII (Factor XIIf ) in plasma, we studied the inactivation kinetics of Factor XIIf in various purified and plasma mixtures. We also analyzed the formation of 125I-Factor XIIf -inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with C-1-inhibitor, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively. Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between 125I-Factor XIIf and each of these three inhibitors. In contrast, kinetic and SDS-PAGE studies indicated that Factor XIIf did not react with alpha 1-antitrypsin or alpha 2-macroglobulin. The inactivation rate constant of Factor XIIf by prekallikrein-deficient plasma was 14.4 X 10(-2) min-1, a value that was essentially identical to the value predicted from the studies in purified systems (15.5 X 10(-2) min-1). This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of C-1-inhibitor. In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III. Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when 125I-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor. This study quantitatively demonstrates the dominant role of C-1-inhibitor in the inactivation of Factor XIIf in the plasma milieu.
为了确定血浆中导致凝血因子 XII 衍生的活性片段(凝血因子 XIIf)失活的因素,我们研究了凝血因子 XIIf 在各种纯化体系和血浆混合物中的失活动力学。我们还通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)分析了 125I-凝血因子 XIIf-抑制剂复合物的形成。在纯化体系中,凝血因子 XIIf 与 C1 抑制剂、α2-抗纤溶酶和抗凝血酶 III 反应的双分子速率常数分别为 18.5、0.91 和 0.32×104 M-1 min-1。此外,SDS-PAGE 分析显示 125I-凝血因子 XIIf 与这三种抑制剂中的每一种都形成了 1:1 的化学计量复合物。相比之下,动力学和 SDS-PAGE 研究表明凝血因子 XIIf 不与α1-抗胰蛋白酶或α2-巨球蛋白反应。缺乏前激肽释放酶的血浆使凝血因子 XIIf 的失活速率常数为 14.4×10-2 min-1,该值与纯化体系研究预测的值(15.5×10-2 min-1)基本相同。当凝血因子 XIIf 被免疫去除(小于 5%)C1 抑制剂的缺乏前激肽释放酶的血浆失活时,该常数降至 1.8×10-2 min-1。此外,在正常血浆中失活后,发现 74%的活性 125I-凝血因子 XIIf 与 C1 抑制剂形成复合物,而 26%的酶与α2-抗纤溶酶和抗凝血酶 III 形成复合物。此外,当 125I-凝血因子 XII 在含有 32%功能性 C1 抑制剂的遗传性血管性水肿血浆中失活时,42%的标记酶仍与 C1 抑制剂复合。这项研究定量地证明了 C1 抑制剂在血浆环境中凝血因子 XIIf 失活中的主导作用。